Key clinical point: Despite failing to best current chemotherapies for relapsed/refractory peripheral T-cell lymphoma, a new report suggests that alisertib might have a role as a last-ditch option.
Major finding: Overall response rate (ORR) was 33% for alisertib versus 45% for the comparator arm (odds ratio, 0.60; 95% confidence interval, 0.33-1.08).
Study details: Open-label trial in 271 relapsed/refractory PTCL patients.
Disclosures: The work was funded by alisertib maker Millennium Pharmaceuticals, a subsidiary of Takeda. Investigators reported various ties to Millennium and Takeda, including research funding, honoraria, and consulting work. The study team included employees of those companies.
Must Reads in Oncology
Consumption of SSBs & Risk of Mortality, Circulation; ePub 2019 Mar 18; Malik, et al
Ultrasonography Screening in Breast Cancer, JAMA Intern Med; ePub 2019 Mar 18; Lee, et al